Valbiotis SA (FR:ALVAL)
:ALVAL
Top Page
Valbiotis SA
(ALVAL)
Select Model
Select Model
Rating:48Neutral
Price Target:
€1.00
▲(38.89% Upside)
Action:ReiteratedDate:03/21/26
The score is held down primarily by weak financial performance driven by persistent losses and continued cash burn with funding/dilution risk. Technicals provide partial support due to price trading above key moving averages, but momentum is not strong. Valuation contributes limited positives because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Preventive nutrition focus
Valbiotis’ focus on clinically substantiated preventive nutrition targets large, structural markets (metabolic and cardiovascular health). Clinical positioning supports sustained demand, institutional partnerships and recurring sales opportunities versus one-off products over the medium term.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow shows the business is not self-funding and depends on external capital. Continued cash burn limits runway, increases dilution risk, and constrains investments in commercialization or R&D over the medium term without new funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Preventive nutrition focus
Valbiotis’ focus on clinically substantiated preventive nutrition targets large, structural markets (metabolic and cardiovascular health). Clinical positioning supports sustained demand, institutional partnerships and recurring sales opportunities versus one-off products over the medium term.
Read all positive factors
Valbiotis SA (ALVAL) vs. iShares MSCI France ETF (EWQ)
Market Cap
€25.30M
Dividend YieldN/A
Average Volume (3M)112.19K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.20
Shares Outstanding23,698,235
10 Day Avg. Volume162,174
30 Day Avg. Volume112,190
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.36
Price to Sales (P/S)18.17
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.35
Revenue Forecast (FY)€4.53M
Valbiotis SA Business Overview & Revenue Model
Company Description
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabet...
How the Company Makes Money
null...
Valbiotis SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
42
Neutral
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 905.00K | 175.00K | 4.73M | 785.00K | 298.00K |
| Gross Profit | -1.17M | -2.44M | 2.69M | 767.00K | 282.00K |
| EBITDA | -9.49M | -9.17M | -6.41M | -11.13M | -9.14M |
| Net Income | -9.42M | -10.03M | -7.37M | -12.31M | -8.68M |
Balance Sheet | |||||
| Total Assets | 14.39M | 19.61M | 33.31M | 27.17M | 28.48M |
| Cash, Cash Equivalents and Short-Term Investments | 8.68M | 11.58M | 25.02M | 20.83M | 21.82M |
| Total Debt | 5.09M | 5.72M | 6.88M | 7.18M | 7.59M |
| Total Liabilities | 7.43M | 9.24M | 13.71M | 13.86M | 14.25M |
| Stockholders Equity | 6.96M | 10.37M | 19.60M | 13.31M | 14.23M |
Cash Flow | |||||
| Free Cash Flow | -8.19M | -11.80M | -8.30M | -9.48M | -7.58M |
| Operating Cash Flow | -8.04M | -11.54M | -8.06M | -9.19M | -7.16M |
| Investing Cash Flow | -77.00K | -61.00K | -250.00K | -197.00K | -7.00K |
| Financing Cash Flow | 5.21M | -1.84M | 12.49M | 8.40M | 14.40M |
Valbiotis SA Technical Analysis
Positive
0.72
Price Trends
0.97
Positive
0.83
Positive
0.83
Positive
Market Momentum
0.01
Positive
56.59
Neutral
42.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALVAL, the sentiment is Positive. The current price of 0.72 is below the 20-day moving average (MA) of 1.01, below the 50-day MA of 0.97, and below the 200-day MA of 0.83, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 56.59 is Neutral, neither overbought nor oversold. The STOCH value of 42.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALVAL.
Valbiotis SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | €7.40M | -15.91 | ― | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | €25.30M | -1.75 | ― | ― | ― | ― | |
47 Neutral | €26.76M | -0.86 | ― | ― | 101.95% | 35.55% | |
45 Neutral | €19.97M | -0.93 | 51.23% | ― | -92.35% | 63.25% |
* Healthcare Sector Average
FR:ALVAL
Valbiotis SA
1.07
-0.04
-3.96%
FR:ALCOX
Nicox SA
0.41
0.15
57.09%
FR:SIGHT
GenSight Biologics SA
0.09
-0.15
-63.68%
FR:ALDVI
Advicenne SA
1.84
0.01
0.66%
FR:ALNFL
NFL Biosciences SA
1.05
-0.65
-38.12%
FR:ALPAT
Plant Advanced Technologies SA
6.56
-3.94
-37.52%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.